Publications by authors named "B Odler"
Therapeutic plasma exchange (PLEX) is an adjunctive treatment for patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis and kidney involvement. Little is known about the effect of PLEX on early changes in kidney function. This post-hoc analysis of the PEXIVAS trial investigated the effects of PLEX on changes in kidney function within 12 months.
View Article and Find Full Text PDFArticle Synopsis
- A retrospective study of 183 adult patients treated with rituximab for podocytopathies showed that 82% achieved complete or partial remission within 6 months.
- *Long-term follow-up revealed that 55% of initial responders maintained relapse-free survival over three years, with improved outcomes linked to maintenance therapy.
- *Patients on maintenance therapy experienced significantly fewer relapses per year and maintained stable kidney function compared to non-responders.
Article Synopsis
- Chronic kidney disease (CKD) is more prevalent in women at stages 3-5 without albuminuria, but most patients receiving kidney replacement therapy are men, indicating a gender disparity influenced by biological and social factors.
- A study used questionnaires to explore CKD patients' and caregivers' views on gender roles and health care, gathering responses from 783 patients and 98 caregivers at clinics in Austria.
- Results showed both male and female patients generally believe women manage their health better and that gender does not affect treatment equality in CKD care, with a strong consensus among caregivers as well.
Objectives: Systemic sclerosis (SSc) is a multiorgan disease with a 10-year mortality rate of up to 50 %. B cell-depleting therapy with rituximab (RTX) appears effective in SSc treatment, but data from randomized controlled trials (RCTs) are lacking, and the frequency and dosage of RTX in SSc have no consensus. We aimed to evaluate the long-term efficacy and safety of quarterly RTX administration in SSc.
View Article and Find Full Text PDF